These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22453849)

  • 1. Patient preferences for different severities of and treatments for overactive bladder.
    Wu JM; Fulton RG; Amundsen CL; Knight SK; Kuppermann M
    Female Pelvic Med Reconstr Surg; 2011 Jul; 17(4):184-9. PubMed ID: 22453849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the effect of overactive bladder symptoms on woman's quality of life during and after first pregnancy?
    Van Brummen HJ; Bruinse HW; Van de Pol G; Heintz AP; Van der Vaart CH
    BJU Int; 2006 Feb; 97(2):296-300. PubMed ID: 16430633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women.
    Teleman PM; Lidfeldt J; Nerbrand C; Samsioe G; Mattiasson A;
    BJOG; 2004 Jun; 111(6):600-4. PubMed ID: 15198789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overactive bladder syndrome: an underestimated long-term problem after treatment of patients with localized prostate cancer?
    Boettcher M; Haselhuhn A; Jakse G; Brehmer B; Kirschner-Hermanns R
    BJU Int; 2012 Jun; 109(12):1824-30. PubMed ID: 21952039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory overactive bladder: Beyond oral anticholinergic therapy.
    Glinski RW; Siegel S
    Indian J Urol; 2007 Apr; 23(2):166-73. PubMed ID: 19675795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences for antimuscarinic therapy for overactive bladder.
    Swinburn P; Lloyd A; Ali S; Hashmi N; Newal D; Najib H
    BJU Int; 2011 Sep; 108(6):868-73. PubMed ID: 21105989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactive bladder in Taiwanese women: re-analysis of epidemiological database of community from 1999 to 2001.
    Chen YC; Ng SC; Chen SL; Huang YH; Hu SW; Chen GD
    Neurourol Urodyn; 2012 Jan; 31(1):56-9. PubMed ID: 21826728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
    Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
    J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.